Gilead Sciences expands lenacapavir licenses and Gilead Sciences stock trades EUR 128.60
Published on 10/03/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences, Inc. announced on September 16, 2026, that it had expanded six royalty-free voluntary licensing agreements for investigational once-yearly lenacapavir to cover 120 high-incidence countries, according to Gilead Sciences. Gilead Sciences stock was at EUR 128.60 in weekend trading at Lang & Schwarz at 10:18 a.m. CEST on October 3, 2026, up 0.04 percent versus the EUR 128.55 close at Lang & Schwarz on October 2, 2026.
Weekend trading at Lang & Schwarz
The EUR 128.60 price represents a EUR 0.05 increase from the EUR 128.55 close at Lang & Schwarz on October 2, 2026. The quoted bid was EUR 128.48 and the ask was EUR 128.72. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
The October 2, 2026 close
Lang & Schwarz recorded the previous close at EUR 128.55 on October 2, 2026. Gilead Sciences is listed on Nasdaq under the ticker GILD, as identified in the company’s September 16 release.
Lenacapavir access planning
The September 16 announcement said the expanded agreements cover 120 high-incidence countries, primarily low- and lower-middle-income countries, and are intended to support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial continues, according to Gilead Sciences. The company said once-yearly lenacapavir for HIV prevention remains investigational and has not been approved by any regulatory authority. On September 15, Gilead also announced an agreement with the Pan American Health Organization to support access to twice-yearly lenacapavir for HIV prevention across PAHO Member States in Latin America and the Caribbean, according to Gilead Sciences.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
